Full Press Release Details
Sinovac Biotech Cures Nasdaq Filing Deficiency
BEIJING, December 1, 2017 /PRNewswire/
-- Sinovac Biotech Ltd. (Nasdaq: SVA)(the "Company" or "Sinovac"), a leading provider of biopharmaceutical
products in China, announced today that it has received a Nasdaq Staff letter indicating that the Form 20-F filing delinquency,
which was the subject of a prior Nasdaq Staff Determination letter, has been cured after the Company filed its annual report on
Form 20-F for the year ended December 31, 2016 with the SEC on November 22, 2017.In the letter, Nasdaq indicated that the Company
is in compliance with all applicable listing standards. As a result, the previously scheduled delisting hearing with the Nasdaq
Listing Qualifications Panel has been canceled.
Sinovac Biotech Ltd. is a China-based
biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect
against human infectious diseases. Sinovac's product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and
B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), and mumps. The EV71 vaccine, an innovative
vaccine developed by Sinovac against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009,
Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese
Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza
vaccine to the government stockpiling program. The Company is developing a number of new products including a Sabin-strain inactivated
polio vaccine, pneumococcal polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells
its vaccines in China, while also exploring growth opportunities in international markets. The Company has exported select vaccines
to over 10 countries in Asia and South America. For more information, please visit the Company's website at www.sinovac.com.
Safe Harbor Statement
This announcement may include
certain statements that are not descriptions of historical facts, but are forward-looking statements. These statements are made
under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking
statements can be identified by terminology such as "will," "expects," "anticipates," "future,"
"intends," "plans," "believes," "estimates" and similar statements. Forward-looking
statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained
in any such statements.
Sinovac Biotech Ltd.
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910
Email: ir@sinovac.com
Email: william.zima@icrinc.com